JP2023548829A5 - - Google Patents

Info

Publication number
JP2023548829A5
JP2023548829A5 JP2023526091A JP2023526091A JP2023548829A5 JP 2023548829 A5 JP2023548829 A5 JP 2023548829A5 JP 2023526091 A JP2023526091 A JP 2023526091A JP 2023526091 A JP2023526091 A JP 2023526091A JP 2023548829 A5 JP2023548829 A5 JP 2023548829A5
Authority
JP
Japan
Prior art keywords
domain
cell
cells
receptor
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023526091A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023548829A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/058138 external-priority patent/WO2022098925A1/en
Publication of JP2023548829A publication Critical patent/JP2023548829A/ja
Publication of JP2023548829A5 publication Critical patent/JP2023548829A5/ja
Pending legal-status Critical Current

Links

JP2023526091A 2020-11-04 2021-11-04 異種腫瘍制御のための操作されたｉＰＳＣ及び免疫エフェクター細胞 Pending JP2023548829A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063109829P 2020-11-04 2020-11-04
US63/109,829 2020-11-04
US202163172891P 2021-04-09 2021-04-09
US63/172,891 2021-04-09
PCT/US2021/058138 WO2022098925A1 (en) 2020-11-04 2021-11-04 Engineered ipsc and immune effector cells for heterogenous tumor control

Publications (2)

Publication Number Publication Date
JP2023548829A JP2023548829A (ja) 2023-11-21
JP2023548829A5 true JP2023548829A5 (OSRAM) 2024-11-12

Family

ID=81458357

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023526091A Pending JP2023548829A (ja) 2020-11-04 2021-11-04 異種腫瘍制御のための操作されたｉＰＳＣ及び免疫エフェクター細胞

Country Status (9)

Country Link
US (1) US20230405121A1 (OSRAM)
EP (1) EP4240832A4 (OSRAM)
JP (1) JP2023548829A (OSRAM)
KR (1) KR20230098637A (OSRAM)
AU (1) AU2021376358A1 (OSRAM)
CA (1) CA3196549A1 (OSRAM)
IL (1) IL302476A (OSRAM)
MX (1) MX2023004325A (OSRAM)
WO (1) WO2022098925A1 (OSRAM)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4106805A4 (en) * 2020-02-20 2024-07-03 Win Therapeutics, Inc. Bispecific gd2 and b7h2 binding molecules and methods of use
KR20230019949A (ko) * 2020-06-03 2023-02-09 리젠츠 오브 더 유니버시티 오브 미네소타 B7h3-표적화 단백질 및 이의 사용 방법
JP7707304B2 (ja) 2022-04-08 2025-07-14 フェイト セラピューティクス，インコーポレイティド 腫瘍標的化のためのキメラ抗原受容体
KR20250005097A (ko) 2022-04-08 2025-01-09 페이트 세러퓨틱스, 인코포레이티드 고형 종양 표적화 골격을 갖는 세포 및 이의 용도
WO2024097800A1 (en) * 2022-11-01 2024-05-10 Fate Therapeutics, Inc. Off-the-shelf therapeutic cells with multiplex genomic engineering for targeting kallikrein-2
WO2024165051A1 (zh) * 2023-02-09 2024-08-15 南京北恒生物科技有限公司 功能增强的细胞疗法
WO2025180514A1 (en) * 2024-03-01 2025-09-04 Qihan Hong Kong Limited Autoimmune disease therapy using engineered cells
WO2025212837A1 (en) * 2024-04-04 2025-10-09 The Regents Of The University Of Michigan Enhanced anti-cancer t-cell therapy

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE051165T2 (hu) * 2015-07-29 2021-03-01 Allergan Inc ANG-2 elleni, csak nehézláncot tartalmazó antitestek
US10562952B2 (en) * 2015-09-10 2020-02-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-CD276 chimeric antigen receptors
CA3068256A1 (en) * 2017-06-21 2018-12-27 The University Of North Carolina At Chapel Hill Methods and compositions for chimeric antigen receptor targeting cancer cells
BR112020005938A2 (pt) * 2017-09-27 2020-11-17 University Of Southern California célula imune ou população de células imunes da mesma, célula efetora imune ou célula-tronco, célula que apresenta antígeno, polinucleotídeo recombinante, vetor, composição que compreende uma célula imune efetora ou uma célula-tronco, métodos para produzir uma célula efetora imune que expressa receptor imune de ocorrência não natural, para gerar uma população de células manipuladas por rna, para fornecer imunidade antidoença em um indivíduo, para tratar ou prevenir uma doença associada à expressão de um antígeno, e, uso
BR112020010597A2 (pt) * 2017-12-08 2020-10-27 Fate Therapeutics, Inc. imunoterapias com o uso de células efetoras derivadas de ipsc intensificadas
WO2019157533A1 (en) * 2018-02-12 2019-08-15 The General Hospital Corporation Chimeric antigen receptors targeting the tumor microenvironment
WO2019197676A1 (en) * 2018-04-13 2019-10-17 Ludwig Institute For Cancer Research Ltd Heterodimeric inactivatable chimeric antigen receptors
CN110950953B (zh) * 2018-09-26 2022-05-13 福州拓新天成生物科技有限公司 抗b7-h3的单克隆抗体及其在细胞治疗中的应用
SG11202105480WA (en) * 2018-12-02 2021-06-29 Fate Therapeutics Inc IMMUNOTHERAPIES USING ENHANCED iPSC DERIVED EFFECTOR CELLS
KR20230019949A (ko) * 2020-06-03 2023-02-09 리젠츠 오브 더 유니버시티 오브 미네소타 B7h3-표적화 단백질 및 이의 사용 방법

Similar Documents

Publication Publication Date Title
JP2022541441A5 (OSRAM)
JP2022550899A5 (OSRAM)
JP2021505131A5 (OSRAM)
JP2023548467A5 (OSRAM)
JP2022548943A5 (OSRAM)
JP7106610B2 (ja) 導入遺伝子の遺伝子タグおよびその使用方法
JP2022510207A5 (OSRAM)
JP2023505206A5 (OSRAM)
JP7623020B2 (ja) 同種異系移植のための操作された免疫細胞
JP2021519061A5 (OSRAM)
JP7767502B2 (ja) Ｎｋ阻害性分子を発現する遺伝子改変免疫細胞とその使用
JP2023530704A5 (OSRAM)
JP2022001067A (ja) キメラ抗体受容体（ＣＡＲｓ）の構成およびその使用方法
EP3169703B1 (en) Chimeric antigen receptor and its use
JP2023545992A5 (OSRAM)
US20230028399A1 (en) Bcma-directed cellular immunotherapy compositions and methods
CN113227379A (zh) 多功能多靶向嵌合抗原受体（car）系统及其使用方法
CN114015656A (zh) 用于同种异体移植的工程化免疫细胞
KR20210126008A (ko) 세포 면역 치료의 조합
EP4194472A1 (en) Chimeric antigen receptor comprising novel co-stimulatory domain and use thereof
KR20230137923A (ko) 신규한 키메라 항원 수용체 및 이의 용도
US20220133792A1 (en) Signaling platforms for chimeric antigen receptor t cells
KR20210021593A (ko) 다양한 구조 최적화를 갖는 t 세포-항원 커플러
JP2024515920A5 (OSRAM)
JP2025105605A5 (OSRAM)